Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02450331




Registration number
NCT02450331
Ethics application status
Date submitted
19/05/2015
Date registered
21/05/2015
Date last updated
18/06/2023

Titles & IDs
Public title
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
Scientific title
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
Secondary ID [1] 0 0
2014-005603-25
Secondary ID [2] 0 0
WO29636
Universal Trial Number (UTN)
Trial acronym
IMvigor010
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Transitional Cell 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Bladder - transitional cell cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Atezolizumab

Experimental: Atezolizumab - Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).

No intervention: Observation - Participants will undergo observation starting on Day 1 for 16 cycles (up to 1 year).


Treatment: Drugs: Atezolizumab
Atezolizumab will be administered at a dose of 1200 milligrams (mg).
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease-Free Survival (DFS), as Assessed by Investigator
Timepoint [1] 0 0
Randomization up to first occurrence of DFS event (up to approximately 50 months)
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Randomization until death due to any cause (up to approximately 80 months)
Secondary outcome [2] 0 0
Disease-Specific Survival (DSS), as Assessed by Investigator
Timepoint [2] 0 0
Randomization until death due to UC (up to approximately 50 months)
Secondary outcome [3] 0 0
Distant Metastasis-Free Survival (DMFS)
Timepoint [3] 0 0
Randomization up to diagnosis of distant metastases or death from any cause (up to approximately 50 months)
Secondary outcome [4] 0 0
Non-Urinary Tract Recurrence-Free Survival (NURFS)
Timepoint [4] 0 0
Randomization up to time of first occurrence of a NURFS event (up to approximately 50 months)
Secondary outcome [5] 0 0
Percentage of Participants With Adverse Events (AEs)
Timepoint [5] 0 0
Screening up to approximately 80 months
Secondary outcome [6] 0 0
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Timepoint [6] 0 0
Baseline up to approximately 50 months
Secondary outcome [7] 0 0
EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score
Timepoint [7] 0 0
Day 1 of Cycle 1 up to approximately 50 months (Cycle length = 21 days)
Secondary outcome [8] 0 0
Minimum Observed Serum Atezolizumab Concentration (Cmin)
Timepoint [8] 0 0
Pre-dose (Hour 0) on Day 1 of Cycles 1, 2, 3, 4, every 8 cycles from Cycle 8, at treatment discontinuation, 120 days after treatment discontinuation (up to approximately 50 months))(Cycle length = 21 days)
Secondary outcome [9] 0 0
Maximum Observed Serum Atezolizumab Concentration (Cmax)
Timepoint [9] 0 0
Day 1 of Cycle 1 (Cycle length = 21 days)

Eligibility
Key inclusion criteria
* Histologically confirmed muscle-invasive UC (also termed transitional cell carcinoma) of the bladder or upper urinary tract (i.e., renal pelvis or ureters)
* For participants treated with prior neoadjuvant chemotherapy: tumor stage of ypT2-4a or ypN+ (ypT2-4 or ypN+ for participants with upper urinary tract UC) and M0
* For participants who have not received prior neoadjuvant chemotherapy: tumor stage of pT3-4a or pN+ (pT3-4 or pN+ for participants with upper urinary tract UC) and M0
* Representative formalin-fixed paraffin-embedded tumor specimens from surgical resection (i.e., radical cystectomy, nephroureterectomy, or lymph node dissection) in paraffin blocks (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor programmed death-ligand 1 (PD-L1) expression prior to study enrollment
* Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging scan of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization
* Full recovery from cystectomy or nephroureterectomy within 14 weeks following surgery
* Eastern Cooperative Oncology Group performance status of less than or equal to (</=) 2
* Life expectancy greater than or equal to (>/=) 12 weeks
* Adequate hematologic and end-organ function
* For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 5 months after the last dose of atezolizumab
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment
* Adjuvant chemotherapy or radiation therapy for UC following surgical resection
* Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug prior to enrollment
* Malignancies other than UC within 5 years prior to Cycle 1, Day 1
* Pregnancy or breastfeeding
* Significant cardiovascular disease
* Severe infections within 4 weeks prior to Cycle 1, Day 1
* Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
* History of autoimmune disease
* Prior allogeneic stem cell or solid organ transplant
* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
* Positive test for human immunodeficiency virus and/or active hepatitis B or hepatitis C or tuberculosis
* Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1
* Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-CD40, anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/10/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/06/2022
Sample size
Target
Accrual to date
Final
809
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Macquarie University Hospital - Macquarie Park
Recruitment hospital [2] 0 0
Royal Brisbane & Women's Hosp; Cancer Care Serv - Herston
Recruitment hospital [3] 0 0
Monash Medical Centre; Oncology - Clayton
Recruitment hospital [4] 0 0
Austin and Repatriation Medical Centre; Cancer Services - Melbourne
Recruitment postcode(s) [1] 0 0
2109 - Macquarie Park
Recruitment postcode(s) [2] 0 0
4029 - Herston
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
3084 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Iowa
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
Rhode Island
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Belgium
State/province [20] 0 0
Anderlecht
Country [21] 0 0
Belgium
State/province [21] 0 0
Bruxelles
Country [22] 0 0
Belgium
State/province [22] 0 0
Gent
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
China
State/province [28] 0 0
Beijing City
Country [29] 0 0
China
State/province [29] 0 0
Beijing
Country [30] 0 0
China
State/province [30] 0 0
Guangzhou City
Country [31] 0 0
China
State/province [31] 0 0
Nanjing City
Country [32] 0 0
China
State/province [32] 0 0
Nanjing
Country [33] 0 0
China
State/province [33] 0 0
Shanghai City
Country [34] 0 0
China
State/province [34] 0 0
Shanghai
Country [35] 0 0
Czechia
State/province [35] 0 0
Brno
Country [36] 0 0
Czechia
State/province [36] 0 0
Olomouc
Country [37] 0 0
Czechia
State/province [37] 0 0
Pardubice
Country [38] 0 0
Czechia
State/province [38] 0 0
Praha 5
Country [39] 0 0
Finland
State/province [39] 0 0
Helsinki
Country [40] 0 0
Finland
State/province [40] 0 0
Tampere
Country [41] 0 0
Finland
State/province [41] 0 0
Turku
Country [42] 0 0
France
State/province [42] 0 0
Angers
Country [43] 0 0
France
State/province [43] 0 0
Avignon
Country [44] 0 0
France
State/province [44] 0 0
Bordeaux
Country [45] 0 0
France
State/province [45] 0 0
Caen
Country [46] 0 0
France
State/province [46] 0 0
Clermont Ferrand
Country [47] 0 0
France
State/province [47] 0 0
Lyon
Country [48] 0 0
France
State/province [48] 0 0
Nancy
Country [49] 0 0
France
State/province [49] 0 0
Nice
Country [50] 0 0
France
State/province [50] 0 0
Paris
Country [51] 0 0
France
State/province [51] 0 0
Saint Herblain
Country [52] 0 0
France
State/province [52] 0 0
Toulouse
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Germany
State/province [54] 0 0
Bochum
Country [55] 0 0
Germany
State/province [55] 0 0
Dresden
Country [56] 0 0
Germany
State/province [56] 0 0
Düsseldorf
Country [57] 0 0
Germany
State/province [57] 0 0
Herne
Country [58] 0 0
Germany
State/province [58] 0 0
Mannheim
Country [59] 0 0
Germany
State/province [59] 0 0
München
Country [60] 0 0
Germany
State/province [60] 0 0
Rostock
Country [61] 0 0
Germany
State/province [61] 0 0
Stuttgart
Country [62] 0 0
Germany
State/province [62] 0 0
Tübingen
Country [63] 0 0
Germany
State/province [63] 0 0
Ulm
Country [64] 0 0
Greece
State/province [64] 0 0
Athens
Country [65] 0 0
Greece
State/province [65] 0 0
Patras
Country [66] 0 0
Israel
State/province [66] 0 0
Hafia
Country [67] 0 0
Israel
State/province [67] 0 0
Jerusalem
Country [68] 0 0
Israel
State/province [68] 0 0
Kfar-Saba
Country [69] 0 0
Israel
State/province [69] 0 0
Petah Tikva
Country [70] 0 0
Israel
State/province [70] 0 0
Ramat Gan
Country [71] 0 0
Israel
State/province [71] 0 0
Tel Aviv
Country [72] 0 0
Israel
State/province [72] 0 0
Zerifin
Country [73] 0 0
Italy
State/province [73] 0 0
Campania
Country [74] 0 0
Italy
State/province [74] 0 0
Emilia-Romagna
Country [75] 0 0
Italy
State/province [75] 0 0
Lazio
Country [76] 0 0
Italy
State/province [76] 0 0
Lombardia
Country [77] 0 0
Italy
State/province [77] 0 0
Piemonte
Country [78] 0 0
Italy
State/province [78] 0 0
Toscana
Country [79] 0 0
Italy
State/province [79] 0 0
Umbria
Country [80] 0 0
Japan
State/province [80] 0 0
Aichi
Country [81] 0 0
Japan
State/province [81] 0 0
Aomori
Country [82] 0 0
Japan
State/province [82] 0 0
Ehime
Country [83] 0 0
Japan
State/province [83] 0 0
Hiroshima
Country [84] 0 0
Japan
State/province [84] 0 0
Hokkaido
Country [85] 0 0
Japan
State/province [85] 0 0
Ibaraki
Country [86] 0 0
Japan
State/province [86] 0 0
Iwate
Country [87] 0 0
Japan
State/province [87] 0 0
Kyoto
Country [88] 0 0
Japan
State/province [88] 0 0
Okayama
Country [89] 0 0
Japan
State/province [89] 0 0
Osaka
Country [90] 0 0
Japan
State/province [90] 0 0
Saitama
Country [91] 0 0
Japan
State/province [91] 0 0
Shizuoka
Country [92] 0 0
Japan
State/province [92] 0 0
Tokyo
Country [93] 0 0
Korea, Republic of
State/province [93] 0 0
Goyang-si
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Seoul
Country [95] 0 0
Netherlands
State/province [95] 0 0
Amsterdam
Country [96] 0 0
Netherlands
State/province [96] 0 0
Groningen
Country [97] 0 0
Netherlands
State/province [97] 0 0
Rotterdam
Country [98] 0 0
Netherlands
State/province [98] 0 0
Utrecht
Country [99] 0 0
Poland
State/province [99] 0 0
Lublin
Country [100] 0 0
Poland
State/province [100] 0 0
Pozna?
Country [101] 0 0
Poland
State/province [101] 0 0
Toru?
Country [102] 0 0
Poland
State/province [102] 0 0
Warszawa
Country [103] 0 0
Poland
State/province [103] 0 0
Wroclaw
Country [104] 0 0
Russian Federation
State/province [104] 0 0
Baskortostan
Country [105] 0 0
Russian Federation
State/province [105] 0 0
Moskovskaja Oblast
Country [106] 0 0
Russian Federation
State/province [106] 0 0
Niznij Novgorod
Country [107] 0 0
Russian Federation
State/province [107] 0 0
Sverdlovsk
Country [108] 0 0
Russian Federation
State/province [108] 0 0
Ivanovo
Country [109] 0 0
Serbia
State/province [109] 0 0
Belgrade
Country [110] 0 0
Spain
State/province [110] 0 0
Barcelona
Country [111] 0 0
Spain
State/province [111] 0 0
Guipuzcoa
Country [112] 0 0
Spain
State/province [112] 0 0
Madrid
Country [113] 0 0
Spain
State/province [113] 0 0
Valencia
Country [114] 0 0
Switzerland
State/province [114] 0 0
Zürich
Country [115] 0 0
Taiwan
State/province [115] 0 0
Taichung
Country [116] 0 0
Taiwan
State/province [116] 0 0
Taipei
Country [117] 0 0
Turkey
State/province [117] 0 0
Adana
Country [118] 0 0
Turkey
State/province [118] 0 0
Edirne
Country [119] 0 0
Turkey
State/province [119] 0 0
Istanbul
Country [120] 0 0
Turkey
State/province [120] 0 0
Kar??yaka
Country [121] 0 0
Ukraine
State/province [121] 0 0
Kharkiv Governorate
Country [122] 0 0
Ukraine
State/province [122] 0 0
Dnipropetrovsk
Country [123] 0 0
Ukraine
State/province [123] 0 0
Kiev
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Birmingham
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Bristol
Country [126] 0 0
United Kingdom
State/province [126] 0 0
Glasgow
Country [127] 0 0
United Kingdom
State/province [127] 0 0
London
Country [128] 0 0
United Kingdom
State/province [128] 0 0
Middlesborough
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Preston
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group.
Trial website
https://clinicaltrials.gov/study/NCT02450331
Trial related presentations / publications
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02450331